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TO THE EDITOR
Despite decades of effort and improved
accuracy of sentinel lymph node detec-
tion, the removal of draining lymph
nodes repeatedly fails to improve mel-
anoma patient mortality (Morton et al.,
2006). The literature is rich with pro
and con arguments regarding the role of
sentinel lymph node biopsy and lymph
node chain removal. The responses to
the article of Morton et al. (A’Hern,
2007; Grichnik, 2007; Kanzler et al.,
2007; Lipsker, 2007; Retsas, 2007;
Thomas, 2007), a commentary by
Gonzales (Gonzalez, 2007) and re-
sponses to that commentary (Cochran
and Thompson, 2008; Morton and
Elashoff, 2008) serve as a window into
this active debate. It is possible that a
different study design or prolonged
follow up will eventually reveal a
survival advantage. It is important to
note the patients with positive sentinel
lymph nodes often receive complete
lymphadenectomy that has significant
morbidity (Guggenheim et al., 2008). It
is also important to note that lympha-
denectomy has thus far failed to im-
prove overall survival in solid tumors
(Gervasoni et al., 2007). However, a
review of these arguments is not the
intent of this paper. Instead the purpose
is to present a hypothesis that may
provide insight into the lack of an
overall survival benefit to lymph node
removal in melanoma patients.
The premise behind sentinel and
lymph node dissections is based on
the assumption that the metastatic cells
enter the lymph system and the lymph
nodes then act as a net capturing the
melanoma cells first in the sentinel
node(s). When the sentinel node fails
to retain all the melanoma cells, then it
is thought that the next node in the
chain will net and hold the released
cancer cells. Certainly an element of
this process is supported by the fact that
with disease progression more lymph
nodes can be found to be involved with
melanoma cells (Morton et al., 2006).
If the premise is correct that lymph
nodes act as a net retaining malignant
melanoma cells, then removal of the
primary and secondary nodes draining
a tumor site should result in a cure as
long as tumor is not found at the end of
the lymph node chain. Unfortunately,
melanoma patients with lymph node
removal still go on to suffer metastatic
disease and die in a similar time frame
to those not undergoing lymph node
removal.
One possible hypothesis is that the
malignant cells merely bypass the
lymph system all together by directly
entering the blood circulatory network.
This is certainly possible given studies
demonstrating direct tumor entry into
the vessels (Warren et al., 1978) and a
correlation of thin melanoma tumor risk
with vascularity (Graham et al., 1994).
However, if the lymph system is the
major mechanism through which tumor
cells leave the primary, then under-
standing the lack of overall survival is
more difficult. Maybe it is due to a
fundamental flaw in our concept of (1)
how lymph nodes function and (2) how
tumors behave.
Hypothesis: A virulent subpopula-
tion of melanoma cells freely traverse
lymph nodes and are subsequently
rapidly disseminated through the vas-
cular system.
HOW DO LYMPH NODES
FUNCTION?
Lymph nodes are perfused by two fluid
channel systems. The first one is a
customary blood circulatory network
with entering arterial and exiting ve-
nous flows. The second is a lymph fluid
channel system entering the node
through afferent vessels and exiting via
efferent vessels (Ohtani et al., 2003).
The blood circulatory network, in
addition to providing for the metabolic
needs of the lymph node, delivers T and
B cells. These cells enter through the
high endothelial vessels, and traverse
nodal tissue (Ohtani et al., 2003). Most
of these cells fail to find an activating
antigen, but rather than leaving the
lymph node via the blood stream they
exit via the efferent lymph system. Cells
that encounter an antigenic target may
locally proliferate but then also leave
via the efferent lymph system. The
number of cells transported back to
the circulatory system from the lymph
nodes has been calculated in the
canine system to be about 245,000
cells per minute per kilogram of weight
(Minnebaev et al., 1981).
Afferent lymph is derived from tissue
fluid and includes essentially any cells,
dissolved or particulate matter that can
be washed into the lymph channel
system. Immune cells that have traveled
into tissue also use the lymph channel
system to return to the circulation. The
afferent lymph vessels enter the lymph
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node and empty into the subcapsular
sinus channel system. This lymph fluid
then has the capacity to bath cells
throughout the lymph node. Macro-
phages and other cells patrol the sinus
membranes and remove target elements
directly from the lymph fluid. The
subcapsular sinus channel system con-
nects to the medullary sinus directly
and indirectly through intermediate
sinus channels, thus allowing for direct
flow between the afferent and efferent
lymph channel systems (Ohtani et al.,
2003). As the afferent and efferent
lymph channels are contiguous, tissue
cells arriving in the afferent lymph that
are not specifically sequestered by
lymph node adherence or cell homing
mechanisms may quickly exit the lymph
node through efferent lymph channels
and subsequently be discharged directly
into the blood circulation.
Thus, lymph nodes do not function
as nets that indiscriminately retain all
cellular material from the tissue they
drain. Instead they function by using
two fluid systems to allow immune cells
to actively interact with tissue drainage.
Cells in the afferent lymph that are not
adherent to the node may freely pass
through the node and exit through the
efferent lymph vessels. Blood-derived
immunoregulatory cells also are dis-
charged into the efferent lymph. The
cellular flow in the efferent lymph back
into the central circulation is impressive
and based on extrapolation from the
canine data it likely exceeds 10 million
cells per minute in the average human.
HOW DO TUMORS BEHAVE?
Many of our carcinogenesis models are
built on the concept that a tissue cell
sequentially accumulates mutations
eventually resulting in a clone with
metastatic behavior. This clone is then
perceived to give rise to a homogenous
population of cells with similar behavior.
However, metastatic melanoma tumors
are not homogeneous and instead are quite
heterogeneous and have been found to
include a subpopulation of cells with
stem-cell-like characteristics (Grichnik,
2008). It is still unclear as to whether
these tumor stem cells represent reten-
tion of characteristics from a tissue stem
cell that gave rise to the tumor or from a
dedifferentiation process from a melano-
cyte. Regardless of origin, it is likely that
they are part of a normal cellular
equilibrium that exists during the devel-
opmental process. The heterogeneity of
these tumors and the plasticity of the
cells (the capacity to become more or
less differentiated along different path-
ways) may explain why this is such a
difficult tumor to eradicate.
As melanomas include cells with
stem-cell-like features, it is appropriate
to consider the mechanisms by which
normal stem cells traverse the body. In
murine studies, it has been demon-
strated that stem cells enter tissue via
the blood stream and after a period of
time in the tissue they then enter the
afferent lymph system (Massberg et al.,
2007; Welner and Kincade, 2007).
These stem cells then appear to directly
pass through the lymph node with little
interference, enter the efferent lymph
system, and then ultimately re-enter the
blood circulation. Thus, normal tissue
stem cells lack the adherence or traf-
ficking factors that drive retention in the
lymph node and thus freely traverse
lymph node structures.
It is interesting to note that in vitro
the melanoma cells with stem-cell-like
features tend to be small in size and are
loosely adherent (Grichnik, 2008), fac-
tors that may allow for increased
passage through the lymph node. Given
that normal stem cells freely traverse
the lymph node tissue, it is rational to
assume that melanoma tumor stem cells
may also do the same. This model does
not exclude the presence of tumor stem
cells in lymph node tissue (as clearly a
subpopulation of cells are present that
can give rise to long term growth
in vitro and in animal systems), just a
greatly increased capacity to pass on
through the nodal tissue. This process
could also be facilitated by increased
lymphangiogeneis (Niakosari et al.,
2008) at the primary tumor site—
allowing more cells to directly enter
the lymphatics.
Clearly some melanoma cells are
retained in lymph nodes. Given the
heterogeneous nature of the melanoma,
it is likely that a subpopulation of the
tumor cells (presumably those more
differentiated) also include adherence
or homing makers that allow for spe-
cific retention in nodal tissue. A major
marker that clearly plays a role in
melanoma lymph node homing is
CCR7 (Murakami et al., 2004). Hetero-
geneous expression of CCR7 has been
noted in melanoma tumors (Takeuchi
et al., 2004). Therefore, some tumor
cells may be more predisposed than
others to be retained in the lymph
nodes. Other tumor cells may express
factors such as CXCR4 or CCR10 and
these proteins might foster attachment/
homing to lung and skin, respectively,
and may account for the differential
metastatic behavior of different mela-
noma tumors (Murakami et al., 2004).
Thus, melanoma tumors behave as
malignant developmental system, with
heterogeneous expression patterns in
the differentiating cells, and a particu-
larly virulent tumor stem cell subpopu-
lation with the capacity to utilize
normal stem cell mechanisms poten-
tially including those allowing direct
passage through lymph node channels.
In summary, it is proposed that the
virulent cells within melanoma tumors
have the capacity to rapidly transit
through lymph tissue and gain access
to the blood circulatory system allow-
ing for widespread dissemination.
These tumor cells likely utilize normal
stem cell mechanisms to accomplish
this task. Although other melanoma
cells may in fact be retained by the
lymph system, their removal with
lymph node dissection does not sig-
nificantly improve overall patient survi-
val due to the fact the cells sequestered
in the nodal tissue are unlikely to cause
a fatal event and that a sufficient
number of virulent cells have already
entered the circulation.
Comments on clinical practice
It is important to keep in mind that this
is a hypothesis. Studies will be required
to verify whether tumor stem cells
readily transverse lymph nodes, or
directly intravasate into the blood
circulatory system. Sentinel node biop-
sies will likely continue to play a role in
patient care but there may also be an
increased use of other prognostic mar-
kers on the primary (such as prolifera-
tive rate) and the use of ultrasound for
evaluating the nodal basins. Certainly
the ultimate objective is to develop
therapeutic approaches beyond just
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early detection to improve melanoma
patient survival.
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TO THE EDITOR
Melanoma occurs in approximately
10% of cases in families with multiple
affected members (De Snoo et al.,
2003). In 20–57% of patients tumor
susceptibility can be attributed to germ-
line inactivating mutations in an allele
of the CDKN2A gene (Goldstein et al.,
2007). A small minority of patients is
predisposed to the development of
melanoma through activating mutations
in the CDK4 gene (Goldstein et al.,
2006). However, in most cases of
familial melanoma the genetic defect
predisposing to melanoma develop-
ment is unknown, which impedes
genetic counseling. The CDKN2A gene
encodes the p16 and p14ARF tumor
suppressor proteins by means of differ-
ent promoters and reading frames.
Inactivation of p16 function through
deletion, point mutation or promoter
hypermethylation is a common and
critical event in the pathogenesis of
melanoma (Sharpless and Chin, 2003;
Singh et al., 2008). In addition, p14ARF
may be genetically or epigenetically
inactivated in sporadic melanoma and
germline mutations in CDKN2A solely
affecting p14ARF function have been
identified in familial melanoma (Har-
land et al., 2005; Furuta et al., 2006).
Patients with familial melanoma not
related to germline mutation in
CDKN2A or CDK4 cannot be distin-
guished on the basis of clinical features.
Germline mutations in different genes
are assumed as a cause of melanoma
predisposition in these patients (Bishop
et al., 2007).
Recently, an alternative mechanism
of tumor predisposition, epimutation or
germline promoter hypermethylation,
has been found. In a subset of patients
with hereditary nonpolyposis colorectal
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